IRI strategic options
This article was originally published in The Tan Sheet
Executive Summary
Chicago-based market researcher has retained William Blair & Co. investment banking firm "to assist the company in its exploration of strategic options," IRI says. Firm's strategic alternatives could include "sale of all or parts of the company, joint ventures, restructuring and capital infusions in order to enhance stockholder value and to better serve our customers," Feb. 26 release states. IRI has been reeling since P&G announced plans to sever its relationship with the share-data provider in July. Chap-Cap Partners investment group, a 5.5% IRI shareholder, sent recent letter demanding IRI Chairman, President and CEO Joseph Durrett step down or sell the firm (1"The Tan Sheet" Feb. 17, 2002 , In Brief)...
You may also be interested in...
IRI on sales block?
Information Resources, Inc. shareholder Chap-Cap Partners pressures Chairman, CEO & President Joseph Durrett in Feb. 13 letter to "sell the company to the highest bidder" before "IRI's shareholders take it upon themselves to find another CEO and board of directors who will do so in your stead." El Segundo, Calif.-based investment group has collected a 5.6% stake in the market research firm since Jan. 8, shortly after Procter & Gamble announced plans to terminate its contract with IRI (1"The Tan Sheet" Dec. 16, 2002, In Brief). IRI reported flat worldwide revenues of $554.8 mil. in 2002 and a $13 mil. net loss, which followed a $3.9 mil. deficit the prior year...
AAM Welcomes Proposal To Update Medicare Part D
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: